{
  "source": "PA-Med-Nec-Stendra.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2024 P 2119-8\nProgram Prior Authorization/Medical Necessity - Erectile Dysfunction\nMedication Stendra® (avanafil)\nP&T Approval Date 2/2017, 3/2018, 3/2019, 4/2020, 6/2021, 6/2022, 7/2023, 7/2024\nEffective Date 10/1/2024\n1. Background:\nStendra (avanafil) is a phosphodiesterase 5 inhibitor (PDE5) indicated for the treatment of erectile\ndysfunction.\nThis prior authorization program is intended to encourage the use of lower cost alternatives. This\nprogram requires a member to try two alternative erectile dysfunction medications before providing\ncoverage for Stendra.\n2. Coverage Criteriaa:\nA. Stendra will be approved based on ALL of the following criteria:\n1. Patient has an organic cause of erectile dysfunction [i.e.: diabetes mellitus, hypertension,\natherosclerosis, drug induced*, hypercholesterolemia, renal insufficiency, neurological\ndisease (e.g. stroke, seizure disorder, demyelinating disease, spinal cord injury, tumor),\nendocrine disorder including hypogonadism, vascular or neurologic disease affecting the\ngenitalia, or history of male genital surgery (including prostatectomy, trauma, or\nirradiation)]\n-AND-\n2. Patient is not receiving nitrate therapy\n-AND-\n3. History of failure, contraindication, or intolerance to two of the following (document\ndrug, date tried and reason for failure):\na. tadalafil (generic Cialis)\nb. vardenafil (generic Levitra)\nc. sildenafil (generic Viagra)\n-AND-\n4. Patient is not concurrently receiving an alternative phosphodiesterase-5 enzyme inhibitor\n(e.g. Cialis, Levitra, Staxyn, or Viagra).\nAuthorization will be issued for 12 months.\n© 2024 UnitedHealthcare Services Inc.\n1\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Examples (not all-inclusive): spironolactone, thiazide diuretics (e.g. chlorthalidone, chlorothia",
    "rage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n*Examples (not all-inclusive): spironolactone, thiazide diuretics (e.g. chlorthalidone, chlorothiazide,\nhydrochlorothiazide), methyldopa, clonidine, guanfacine, reserpine, beta-blockers (e.g. propranolol,\nmetoprolol), digoxin, tricyclic antidepressants (e.g. amitriptyline, doxepin, imipramine, nortriptyline,\nprotriptyline), selective serotonin reuptake inhibitors (e.g. citalopram, escitalopram, fluoxetine,\nfluvoxamine, paroxetine, sertraline), duloxetine, venlafaxine, cimetidine, phenytoin, carbamazepine,\nphenobarbital, primidone, lithium carbonate, chlorpromazine, thioridazine, fluphenazine, trifluoperazine,\nfinasteride, dutasteride, chronic use of opioids, estrogens, anti-androgens (e.g. bicalutamide, flutamide,\nnilutamide), luteinizing hormone releasing hormone agonists (leuprolide, histrelin, goserelin, triptorelin)\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization\nbased solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.\nUse of automated approval and re-approval processes varies by program and/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Stendra [package insert]. Freehold, NJ: Metuchen Pharmaceuticals, LLC; November 2022.\n2. Drugs That May Cause Male Sexual Dysfunction. Pharmacist’s Letter. Detail Document\n#220907. September 2006.\n3. Burnett AL, Nehra A, Breau RH, et al. Erectile Dysfunction: AUA Guideline. American\nUrological Association. 2018.\nProgram Prior Authorization/Medical Necessity – Stendra\nChange Control\nDate Change\n2/2017 New program.\n3/2018 Annual review. Clarified existing criteria with no change to intent and\nupdated references.\n3/2019 Changed the required step agents from brand Cialis to generic tadalafil\nand brand Levitra to generic vardenafil. Updated references.\n4/2020 Updated references.\n6/2021 Annual r",
    "dated references.\n3/2019 Changed the required step agents from brand Cialis to generic tadalafil\nand brand Levitra to generic vardenafil. Updated references.\n4/2020 Updated references.\n6/2021 Annual review. Updated references.\n6/2022 Annual review. Updated references.\n7/2023 Annual review. Updated references.\n7/2024 Annual review. Updated references.\n© 2024 UnitedHealthcare Services Inc.\n2"
  ]
}